Drug Profile
Research programme: beta cell replication therapeutics - Evotec SE/Harvard
Alternative Names: CureBetaLatest Information Update: 26 Sep 2019
Price :
$50
*
At a glance
- Originator Harvard University; Howard Hughes Medical Institute
- Developer Evotec SE; Harvard University
- Class Hormones; Small molecules
- Mechanism of Action Cell division stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetes mellitus
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Diabetes-mellitus in Germany
- 04 Nov 2017 No recent reports of development identified for research development in Diabetes-mellitus in USA
- 12 Aug 2014 Research programme: beta cell replication therapeutics - Evotec/Harvard is available for licensing as of 12 Aug 2014. http://www.evotec.com